journal article·2017-07Open access

Chitosan-based silver nanoparticles: A study of the antibacterial, antileishmanial and cytotoxic effects

Douglas dos Santos Lima, Beatriz Gullon, Alejandra Cardelle-Cobas, Lucas M Brito, Klinger AF Rodrigues, Patrick V Quelemes, Joilson Ramos-Jesus, Daniel DR Arcanjo, Alexandra Plácido, Krystallenia Batziou, Pedro Quaresma, Peter Eaton, Cristina Delerue-Matos, Fernando Aecio A Carvalho, Durcilene Alves da Silva, Manuela Pintado, Jose Roberto de SA Leite

Abstract

Silver nanoparticles have been studied as an alternative for treatment of microbial infections and leishmaniasis, without promoting induction of microbial or parasite resistance. In this study, chitosan-based silver nanoparticles were synthesized from silver nitrate (AgNO 3 ), sodium borohydride as a reducing agent, and the biopolymer chitosan as a capping agent. The chitosan-based silver nanoparticles were characterized by ultraviolet–visible, Fourier transform infrared, dynamic light scattering, zeta potential, atomic force microscopy, and transmission electron microscope. The antibacterial assay was performed by determination of the minimum inhibitory concentration. The antileishmanial and the cytotoxic effects induced by AgNO 3 , chitosan, and chitosan-based silver nanoparticles were analyzed by resazurin and MTT colorimetric assays, respectively. AgNO 3 , chitosan, and chitosan-based silver nanoparticles induced a marked activity against all bacterial strains and promastigote forms of Leishmania amazonensis at minimum inhibitory concentrations ranging from 1.69 to 3.38 µg Ag/mL. Interestingly, the chitosan-based silver nanoparticles presented less cytotoxicity than the AgNO 3 alone and were more active against L. amazonensis than solely chitosan. Furthermore, the cytotoxic concentrations (CC 50 ) of both chitosan and chitosan-based silver nanoparticles against macrophages were significantly higher than the IC 50 against promastigotes. Thus, the chitosan-based silver nanoparticles represent a promising alternative for the treatment of microbial infections and leishmaniasis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticles: synthesis and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Center for Biodiversity and Biotechnology (BIOTEC), Federal University of Piauí (UFPI), Parnaíba, Brazil

Medicinal Plants Research Center (NPPM), Federal University of Piauí (UFPI), Teresina, Brazil

Center for Biotechnology and Fine Chemistry, Catholic University of Portugal, Porto, Portugal

Department of Chemical Engineering, Institute of Technology, University of Santiago de Compostela, Santiago de Compostela, Spain

REQUIMTE/LAQV, Polytechnic Institute of Porto (ISEP), Porto, Portugal

UCIBIO/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, Porto University, Porto, Portugal

Area of Morphology, Faculty of Medicine, University of Brasilia (UnB), Brasilia, Brazil

Funding

Spanish Ministry of Economy and Competitiveness · Fundação para a Ciência e a Tecnologia de Portugal

References (53)

Show source-provided references
1. 10.1016/S1381-5148(00)00038-910.1016/S1381-5148(00)00038-9 ↗
2. 10.1023/A:101192901660110.1023/A:1011929016601 ↗
3. 10.1016/j.carbpol.2007.12.01210.1016/j.carbpol.2007.12.012 ↗
4. 10.1016/j.ijbiomac.2008.09.00710.1016/j.ijbiomac.2008.09.007 ↗
5. 10.1016/j.addr.2008.03.01310.1016/j.addr.2008.03.013 ↗
6. 10.1016/j.jinorgbio.2008.12.01710.1016/j.jinorgbio.2008.12.017 ↗
7. 10.1016/j.nano.2015.11.01610.1016/j.nano.2015.11.016 ↗
8. 10.1016/j.ica.2008.04.04210.1016/j.ica.2008.04.042 ↗
9. 10.1016/j.suc.2008.09.00210.1016/j.suc.2008.09.002 ↗
10. 10.1016/j.carres.2009.09.00110.1016/j.carres.2009.09.001 ↗
11. 10.1007/s13204-012-0180-y10.1007/s13204-012-0180-y ↗
12. 10.1016/j.micpath.2016.02.00910.1016/j.micpath.2016.02.009 ↗
13. 10.1016/j.freeradbiomed.2014.09.00510.1016/j.freeradbiomed.2014.09.005 ↗
14. 10.1016/j.exppara.2016.04.00810.1016/j.exppara.2016.04.008 ↗
15. 10.1155/2014/64693210.1155/2014/646932 ↗
16. 10.3390/ijms1403496910.3390/ijms14034969 ↗
17. 10.4067/S0716-9760201200020000210.4067/S0716-97602012000200002 ↗
18. 10.1046/j.1432-1327.2000.01606.x10.1046/j.1432-1327.2000.01606.x ↗
19. 10.1007/s00436-006-0126-y10.1007/s00436-006-0126-y ↗
20. Esmaeili J, Mohebali M, Edrissian GH, . Evaluation of miltefosine against Leishmania major (MRHO/IR/75/ER): in vitro and in vivo studies. Acta Med Iran 2008; 46: 191–196.
21. 10.1016/j.carres.2004.09.00710.1016/j.carres.2004.09.007 ↗
22. 10.1088/0957-4484/19/01/01560310.1088/0957-4484/19/01/015603 ↗
23. 10.1021/bm070155010.1021/bm0701550 ↗
24. Hafdani FN, Sadeghinia N. A review on application of chitosan as a natural antimicrobial. Int J Med Heal Biomed Bioeng Pharm Eng 2011; 5: 46–50.
25. 10.1128/AAC.34.10.201910.1128/AAC.34.10.2019 ↗
26. 10.1128/AEM.66.1.80-86.200010.1128/AEM.66.1.80-86.2000 ↗
27. 10.1016/S0144-8617(00)00200-910.1016/S0144-8617(00)00200-9 ↗
28. 10.1111/j.1751-7915.2008.00080.x10.1111/j.1751-7915.2008.00080.x ↗
29. 10.1016/S0168-1605(01)00717-610.1016/S0168-1605(01)00717-6 ↗
30. 10.1016/j.progpolymsci.2004.04.00110.1016/j.progpolymsci.2004.04.001 ↗
31. 10.1177/0022034597076002070110.1177/00220345970760020701 ↗
32. 10.1002/1097-4628(20010214)79:7<1324::AID-APP210>3.0.CO;2-L10.1002/1097-4628(20010214)79:7<1324::AID-APP210>3.0.CO;2-L ↗
33. 10.1021/bm034130m10.1021/bm034130m ↗
34. 10.1021/jf061310p10.1021/jf061310p ↗
35. 10.1186/2228-5326-2-3210.1186/2228-5326-2-32 ↗
36. 10.1016/j.saa.2005.05.00210.1016/j.saa.2005.05.002 ↗
37. 10.1016/j.nano.2006.12.00110.1016/j.nano.2006.12.001 ↗
38. 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-310.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3 ↗
39. 10.1128/AEM.69.7.4278-4281.200310.1128/AEM.69.7.4278-4281.2003 ↗
40. 10.1186/1556-276X-8-9310.1186/1556-276X-8-93 ↗
41. 10.1155/2013/69348610.1155/2013/693486 ↗
42. 10.3233/BME-13077210.3233/BME-130772 ↗
43. 10.1016/j.eurpolymj.2015.03.06610.1016/j.eurpolymj.2015.03.066 ↗
44. 10.1007/s00436-012-2866-110.1007/s00436-012-2866-1 ↗
45. 10.2147/IJN.S2388310.2147/IJN.S23883 ↗
46. 10.1016/j.tiv.2013.06.00210.1016/j.tiv.2013.06.002 ↗
47. Ribeiro TG, Franca JR, Fuscaldi LL, . An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis. Int J Nanomedicine 2014; 9: 5341–5353.
48. 10.1016/j.carbpol.2010.08.00410.1016/j.carbpol.2010.08.004 ↗
49. 10.1002/cmdc.20090004910.1002/cmdc.200900049 ↗
50. 10.1016/j.colsurfb.2014.08.01810.1016/j.colsurfb.2014.08.018 ↗
51. 10.3390/molecules2005885610.3390/molecules20058856 ↗
52. 10.1016/j.biomaterials.2008.07.03410.1016/j.biomaterials.2008.07.034 ↗
53. Zeledón RA. Hemoflagellates. In: Baron S (ed.) Medical microbiology. University of Texas Medical Branch at Galveston http://www.ncbi.nlm.nih.gov/pubmed/21413333 (1996 accessed 13 September 2016).